This company has been marked as potentially delisted and may not be actively trading. Proteon Therapeutics (PRTO) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock PRTO vs. PLX, IKT, IZTC, CVM, ZIVO, CRTX, JATT, ALVR, FNCH, and AIMShould you be buying Proteon Therapeutics stock or one of its competitors? The main competitors of Proteon Therapeutics include Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), CEL-SCI (CVM), ZIVO Bioscience (ZIVO), Cortexyme (CRTX), JATT Acquisition (JATT), AlloVir (ALVR), Finch Therapeutics Group (FNCH), and AIM ImmunoTech (AIM). These companies are all part of the "medical" sector. Proteon Therapeutics vs. Its Competitors Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies CEL-SCI ZIVO Bioscience Cortexyme JATT Acquisition AlloVir Finch Therapeutics Group AIM ImmunoTech Proteon Therapeutics (NASDAQ:PRTO) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability. Do analysts recommend PRTO or PLX? Protalix BioTherapeutics has a consensus price target of $15.00, suggesting a potential upside of 693.65%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Proteon Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Proteon Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, PRTO or PLX? Proteon Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Is PRTO or PLX more profitable? Proteon Therapeutics has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Proteon Therapeutics' return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Proteon TherapeuticsN/A N/A -118.68% Protalix BioTherapeutics -21.03%-30.89%-11.74% Which has preferable earnings and valuation, PRTO or PLX? Protalix BioTherapeutics has higher revenue and earnings than Proteon Therapeutics. Proteon Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProteon TherapeuticsN/AN/A-$20.73M-$1.15-2.77Protalix BioTherapeutics$61.95M2.43$8.31M$0.0727.00 Do insiders and institutionals have more ownership in PRTO or PLX? 23.0% of Proteon Therapeutics shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 45.7% of Proteon Therapeutics shares are owned by insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor PRTO or PLX? In the previous week, Proteon Therapeutics' average media sentiment score of 0.00 equaled Protalix BioTherapeutics'average media sentiment score. Company Overall Sentiment Proteon Therapeutics Neutral Protalix BioTherapeutics Neutral SummaryProtalix BioTherapeutics beats Proteon Therapeutics on 7 of the 13 factors compared between the two stocks. Get Proteon Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTO vs. The Competition Export to ExcelMetricProteon TherapeuticsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.75M$294.28M$5.79B$10.40BDividend YieldN/AN/A5.63%4.60%P/E Ratio-2.77N/A80.4326.78Price / SalesN/A423.63534.22123.54Price / CashN/A22.4437.9961.55Price / Book-53.179.9815.776.40Net Income-$20.73M-$115.81M$3.30B$271.80M Proteon Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTOProteon TherapeuticsN/A$3.19-0.6%N/A+67.2%$70.75MN/A-2.7717PLXProtalix BioTherapeutics1.8734 of 5 stars$1.90-2.8%$15.00+691.6%+64.3%$151.09M$61.95M-14.58200IKTInhibikase Therapeutics1.2745 of 5 stars$1.61+3.2%$6.50+303.7%+41.4%$119.90MN/A-0.606IZTCInvizyne TechnologiesN/A$12.40flatN/AN/A$77.53MN/A0.0029CVMCEL-SCI1.1727 of 5 stars$9.49-0.4%N/A-74.0%$65.55MN/A-19.8443Positive NewsShort Interest ↓ZIVOZIVO Bioscience0.1238 of 5 stars$13.00-2.3%N/A-3.6%$49.62M$15.85K-2.6610CRTXCortexymeN/A$1.62+1.3%N/A+119.0%$48.85MN/A-0.5555JATTJATT AcquisitionN/A$1.92-4.0%N/A-50.4%$33.12MN/A0.003High Trading VolumeALVRAlloVirN/A$5.01+35.0%N/A-75.8%$25.27MN/A-0.25110High Trading VolumeFNCHFinch Therapeutics GroupN/A$12.40flatN/A+4.6%$19.91MN/A-1.41190Gap DownAIMAIM ImmunoTech1.943 of 5 stars$2.52+0.8%$275.00+10,812.7%-90.8%$6.83M$121K-5.3620Gap Up Related Companies and Tools Related Companies Protalix BioTherapeutics Alternatives Inhibikase Therapeutics Alternatives Invizyne Technologies Alternatives CEL-SCI Alternatives ZIVO Bioscience Alternatives Cortexyme Alternatives JATT Acquisition Alternatives AlloVir Alternatives Finch Therapeutics Group Alternatives AIM ImmunoTech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTO) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Proteon Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Proteon Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
